Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806026 | 0.87 | CHRNA7 (0.47) | MAPTCHRNA7KCNH2FGFR1NAMPT | |
| SCHEMBL2809464 | 0.87 | OPRK1 (0.43) | MAPTRAB9ASMN1; SMN2FGFR1NAMPT | |
| SCHEMBL2802254 | 0.86 | FGFR1 (0.49) | FGFR1EGFRFGFR2FGFR4FGFR3 | |
| SCHEMBL2802707 | 0.85 | CHRNA7 (0.44) | CHRNA7KCNH2FGFR1 | |
| SCHEMBL2803086 | 0.85 | CHRNA7 (0.45) | CHRNA7KCNH2FGFR1EGFRFGFR2 | |
| SCHEMBL14644925 | 0.84 | HTT (0.46) | ALDH1A1RAB9ASMN1; SMN2FGFR1GAA | |
| SCHEMBL2804869 | 0.84 | RIPK1 (0.41) | MAPTALDH1A1CHRNA7KCNH2FGFR1 | |
| SCHEMBL2807118 | 0.84 | FGFR1 (0.51) | MAPTSMN1; SMN2FGFR1EGFRFGFR2 | |
| SCHEMBL2803008 | 0.83 | TRPV1 (0.43) | MAPTALDH1A1CHRNA7KCNH2SMN1; SMN2 | |
| SCHEMBL16360108 | 0.83 | FGFR1 (0.47) | RAB9AFGFR1EGFRFGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379506-B1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2379506-B1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010078421-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F] ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | NQO1, DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPT 1884/4885ALDH1A1 510/4885RAB9A 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.